ABNX.PA • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold ABNX.PA in your mock portfolio yet.
ABIONYX Pharma SA is currently loss-making, as indicated by its negative EPS and PE ratio. The absence of profits suggests that the investment case is driven more by future expectations than by current financial strength, which increases risk for shareholders. Without evidence of improving earnings trends, the financial profile remains weak.
The stock has declined 16.9% over the last month, signaling recent negative momentum, yet it still trades well above its 200-day moving average, indicating a longer-term uptrend remains intact. An RSI of 55.04 suggests the stock is neither overbought nor oversold, pointing to a relatively balanced near-term technical setup. Overall, technicals are mixed: short-term pressure against a still-positive longer-term trend.
Alternative data show a very small digital and hiring footprint, which limits evidence of strong commercial traction or rapid organizational scaling. Web traffic is modest, and social media followings on Twitter/X and LinkedIn, while growing slightly, remain low for a listed company. The absence of job openings suggests limited near-term expansion activity.
Overall, ABIONYX Pharma SA presents a high-risk profile characterized by ongoing losses, modest alternative data signals, and recent negative price momentum. While the stock trades above its 200-day moving average, indicating some residual longer-term optimism, the lack of profitability and weak external traction indicators tilt the outlook to the downside. The investment thesis currently depends heavily on future execution and milestones rather than demonstrated financial strength.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: